Inhibition of Dihydrotestosterone Synthesis in Prostate Cancer by Combined Frontdoor and Backdoor Pathway Blockade by Fiandalo, Michael V. et al.
University of Kentucky
UKnowledge
Center for Pharmaceutical Research and Innovation
Faculty Publications Pharmaceutical Research and Innovation
1-10-2018
Inhibition of Dihydrotestosterone Synthesis in
Prostate Cancer by Combined Frontdoor and
Backdoor Pathway Blockade
Michael V. Fiandalo
Roswell Park Cancer Institute
John J. Stocking
Roswell Park Cancer Institute
Elena A. Pop
Roswell Park Cancer Institute
John H. Wilton
Roswell Park Cancer Institute
Krystin M. Mantione
Roswell Park Cancer Institute
See next page for additional authors
Right click to open a feedback form in a new tab to let us know how this document benefits you.Follow this and additional works at: https://uknowledge.uky.edu/cpri_facpub
Part of the Cancer Biology Commons, Pharmacy and Pharmaceutical Sciences Commons, and
the Urology Commons
This Article is brought to you for free and open access by the Pharmaceutical Research and Innovation at UKnowledge. It has been accepted for
inclusion in Center for Pharmaceutical Research and Innovation Faculty Publications by an authorized administrator of UKnowledge. For more
information, please contact UKnowledge@lsv.uky.edu.
Repository Citation
Fiandalo, Michael V.; Stocking, John J.; Pop, Elena A.; Wilton, John H.; Mantione, Krystin M.; Li, Yun; Attwood, Kristopher M.;
Azabdaftari, Gissou; Wu, Yue; Watt, David S.; Wilson, Elizabeth M.; and Mohler, James L., "Inhibition of Dihydrotestosterone
Synthesis in Prostate Cancer by Combined Frontdoor and Backdoor Pathway Blockade" (2018). Center for Pharmaceutical Research
and Innovation Faculty Publications. 3.
https://uknowledge.uky.edu/cpri_facpub/3
Authors
Michael V. Fiandalo, John J. Stocking, Elena A. Pop, John H. Wilton, Krystin M. Mantione, Yun Li, Kristopher
M. Attwood, Gissou Azabdaftari, Yue Wu, David S. Watt, Elizabeth M. Wilson, and James L. Mohler
Inhibition of Dihydrotestosterone Synthesis in Prostate Cancer by Combined Frontdoor and Backdoor Pathway
Blockade
Notes/Citation Information
Published in Oncotarget, v. 9, no. 13, p. 11227-11242.
Copyright: Fiandalo et al.
This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0
(CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Digital Object Identifier (DOI)
https://doi.org/10.18632/oncotarget.24107
This article is available at UKnowledge: https://uknowledge.uky.edu/cpri_facpub/3
Oncotarget11227www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2018, Vol. 9, (No. 13), pp: 11227-11242
Inhibition of dihydrotestosterone synthesis in prostate cancer 
by combined frontdoor and backdoor pathway blockade
Michael V. Fiandalo1, John J. Stocking1, Elena A. Pop1, John H. Wilton1,2, Krystin M. 
Mantione2, Yun Li1, Kristopher M. Attwood3, Gissou Azabdaftari4, Yue Wu1, David 
S. Watt5, Elizabeth M. Wilson6 and James L. Mohler1
1Department of Urology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
2Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
3Department of Biostatistics and Bioinformatics Roswell Park Cancer Institute, Buffalo, NY 14263, USA
4Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
5Center for Pharmaceutical Research and Innovation and Department of Molecular and Cellular Biochemistry, University of 
Kentucky, Lexington, KY 40536, USA
6Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC 27599, USA
Correspondence to: James L. Mohler, email: James.Mohler@RoswellPark.org
Keywords: androstanediol; dihydrotestosterone; dutasteride; 3α-oxidoreductases; androgen deprivation therapy
Received: September 06, 2017    Accepted: November 19, 2017    Published: January 10, 2018
Copyright: Fiandalo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC 
BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
Androgen deprivation therapy (ADT) is palliative and prostate cancer (CaP) 
recurs as lethal castration-recurrent/resistant CaP (CRPC). One mechanism that 
provides CaP resistance to ADT is primary backdoor androgen metabolism, which 
uses up to four 3α-oxidoreductases to convert 5α-androstane-3α,17β-diol (DIOL) 
to dihydrotestosterone (DHT). The goal was to determine whether inhibition of 
3α-oxidoreductase activity decreased conversion of DIOL to DHT. Protein sequence 
analysis showed that the four 3α-oxidoreductases have identical catalytic amino acid 
residues. Mass spectrometry data showed combined treatment using catalytically 
inactive 3α-oxidoreductase mutants and the 5α-reductase inhibitor, dutasteride, 
decreased DHT levels in CaP cells better than dutasteride alone. Combined blockade 
of frontdoor and backdoor pathways of DHT synthesis provides a therapeutic strategy 
to inhibit CRPC development and growth.
INTRODUCTION
Prostate cancer (CaP) growth and progression rely 
on the activation of the androgen receptor (AR) by the 
testicular androgen, testosterone (T), or its more potent 
metabolite, dihydrotestosterone (DHT) [1]. Almost all 
men who present with advanced CaP and some men who 
fail potentially curative therapy are treated with androgen 
deprivation therapy (ADT). ADT lowers circulating T 
levels, deprives AR of ligand and induces CaP regression 
[2, 3]; however, ADT is only a temporary palliative 
measure. After ADT, intratumoral androgen levels remain 
sufficient to activate AR [1, 4] and CaP recurs as lethal, 
castration-recurrent/resistant CaP (CRPC). 
One mechanism that may contribute to CaP resistance 
to ADT is intratumoral DHT synthesis from adrenal 
androgens or T [5]. Three androgen pathways produce 
DHT (Figure 1A, modified from [6]) from three different, 
penultimate precursors: reduction of the ∆4-double bond in T 
by 5α-reductase (SRD5A) 1, 2 or 3; reduction of the 17-keto 
group in 5α-androstane-3,17-dione (5α-dione) by ARK1C3 
or HSD17B3; or oxidation of the 3α-hydroxyl group in 
5α-androstane-3α,17β-diol (DIOL) by 3α-oxidoreductases. 
The frontdoor pathway uses the adrenal androgens, 
dehydroepiandrosterone (DHEA) or 4-androstene-3,17-dione 
(ASD), as precursors to generate T that undergoes reduction 
to DHT by SRD5A 1, 2 or 3 [7]. Two backdoor pathways 
generate DHT without using T as an intermediate. The 
primary and secondary backdoor pathways convert DIOL or 
5α-dione, respectively, to DHT (Figure 1A). 
Previous work from our laboratory and others 
demonstrated that CaP cells use both primary and 
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secondary backdoor pathways to synthesize DHT [5, 
8–10]. The terminal step in the primary backdoor pathway 
is the conversion of DIOL to DHT [5, 10, 11] by any of 
the four 3α-oxidoreductases: [1] 17β-hydroxysteroid 
dehydrogenase (HSD) 6 (HSD17B6); [2] retinol 
dehydrogenase (RDH) 16 (RDH16); [3] dehydrogenase/
reductase family member 9 (DHRS9, formerly RDH15); 
and [4] dehydrogenase/reductase family member 5 
(RDH5) [5, 11–13]. The secondary backdoor pathway 
involves the conversion of DHEA to ASD by HSD3B1 or 
HSD3B2. ASD is converted subsequently to 5α-dione by 
SRD5A1 and 5α-dione is converted to DHT by AKR1C3 
or HSD17B3 [9, 14–16]. 
Androgen metabolism inhibitors, such as the 
SRD5A inhibitor, dutasteride, or the CYP17A1 inhibitor, 
abiraterone [7, 17], have been disappointing clinically. 
Dutasteride inhibited SRD5A activity [18], depressed 
T uptake and lowered DHT levels in vitro [19], but 
dutasteride proved ineffective against CRPC in a Phase II 
clinical trial [20]. CYP17A1 metabolized steroids, such as 
pregnenolone or progesterone to adrenal androgens, such 
as DHEA, that provided intermediates for the androgen 
pathways that generated T and DHT [21]. Abiraterone 
decreased intratumoral DHT levels [22], but abiraterone 
extended survival by only approximately 4 months [23]. 
CaP resistance to abiraterone presumably resulted from 
enzyme redundancy, progesterone accumulation that led 
to increased CYP17A1 expression and/or the generation 
of AR splice variants [24–27]. The need to produce an 
androgen metabolism inhibitor that performs better than 
abiraterone has become more important since abiraterone 
will become used earlier in the disease as a result of the 
demonstration of improved survival when used with 
standard ADT for newly diagnosed metastatic CaP [28, 
29].
No inhibitors are available clinically to block the 
conversion of DIOL to DHT by 3α-oxidoreductases. 
In this report, we show that the catalytic activity of 
the 3α-oxidoreductases is critical for metabolism of 
5α-androstan-3α-ol-17-one (androsterone; AND) to 
5α-dione and DIOL to DHT. Inhibition of the terminal 
steps of the frontdoor pathway using dutasteride and 
the primary backdoor pathway using 3α-oxidoreductase 
catalytic mutants lowered DHT more effectively than 
either alone.
RESULTS
3α-oxidoreductase enzymes shared a conserved 
catalytic site 
The primary backdoor pathway uses one or more of 
four 3α-oxidoreductases to convert DIOL to DHT or AND 
to 5α-dione (Figure 1B). DHT synthesis from adrenal 
androgens was suggested to contribute to the development 
and growth of CRPC [5, 8, 10, 30]. Inhibition of a single 
3α-oxidoreductase enzyme could fail due to enzyme 
redundancy and/or expression of more than one enzyme. 
Therefore, an optimal therapeutic approach is to inhibit 
all four 3α-oxidoreductases. Constraint-based Multiple 
Protein Alignment Tool (COBALT) protein sequence 
analysis showed that the four 3α-oxidoreductases shared a 
common catalytic site (Figure 1C). 
HSD17B6, RDH16, DHRS9 and RDH5 were 
expressed in clinical CaP
Analysis of immunohistochemistry (IHC) performed 
on Tissue Micro Array sections from a total of 72 patients 
showed that HSD17B6, RDH16, DHRS9 and RDH5 were 
expressed in androgen-stimulated (AS) benign prostate 
(BP), AS-CaP and CRPC (Figure 1D). DHRS9 was 
expressed only in the cytoplasm. Nuclear expression levels 
of HSD17B6 and RDH16, but not RDH5, were higher in 
CRPC tissues than in AS-BP or AS-CaP tissues (Figure 
1E; Supplementary Table 4). RDH16 levels were higher in 
the nucleus than the cytoplasm (Figure 1E; Supplementary 
Table 4). Peri-nuclear enhancement was observed for each 
3α-oxidoreductase except DHRS9, in AS-BP, AS-CaP and 
CRPC tissues. 
3α-oxidoreductase gene expression varied among 
CaP cell lines
Although 3α-oxidoreductases were detected in 
clinical samples using IHC, they were not detectable in 
CaP cell lines using western blot analysis. Therefore, 
quantitative real-time polymerase chain reaction (qRT-
PCR) was performed to determine 3α-oxidoreductase, 
SRD5A and AR gene expression profiles in CaP cell 
lines and the androgen-dependent human CWR22 and 
castration-recurrent CWR22 (rCWR22) CaP  xenografts. 
RDH5 mRNA levels were higher than the expression 
of the other three 3α-oxidoreductases in all cell lines, 
except VCaP, PC-3 and DU145 (Figure 2A). SRD5A3 
mRNA levels were higher than SRD5A1 in all cell lines, 
except PC-3 and DU145 (Figure 2B). SRD5A2 mRNA 
was not measurable, which is consistent with reports of 
low SRD5A2 gene expression in CaP cell lines [19] and 
clinical specimens [31]. AR mRNA was expressed in 
all CaP cell lines, except PC-3 and DU145, and in both 
xenografts (Figure 2C) [32, 33]. The data suggested that 
analysis of 3α-oxidoreductase activity in human CaP cell 
lines required transient expression.
DHT levels increased when RDH16, DHRS9 or 
RDH5 were expressed in LAPC-4 cells
The effect of 3α-oxidoreductase expression on DHT 
levels was determined in the androgen-sensitive LAPC-4 
cell line that expressed wild-type AR and RDH5 (Figure 
2A) and exhibited 5α-reductase activity [19]. VCaP and 
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LNCaP-RPCI (LNCaP) cells [19] were not used initially 
because conversion of T to DHT was not detected. Wild-
type 3α-oxidoreductases were expressed transiently in 
LAPC-4 cells. Results were compared to LAPC-4 cells 
transfected with empty plasmid, which were expected to 
have low endogenous 3α-oxidoreductase activity based on 
endogenous RDH5 in LAPC-4 cells (Figure 2A). LAPC-
4 cells were treated with DIOL, AND or T. DIOL and 
AND were used for treatment because 3α-oxidoreductases 
convert DIOL to DHT or AND to 5α-dione (Figure 1B) [5, 
12, 13]. T treatment was used as a control condition because 
3α-oxidoreductases do not convert T to DHT [12, 13]. 
Liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) analysis revealed that LAPC-4 cells 
transfected with empty plasmid in Serum Free Complete 
Media (SFM; medium without exogenous androgen) 
produced low levels of DHT (0.0211 pmoles/mg protein) 
(Figure 3A empty plasmid). This finding was consistent 
Figure 1: HSD17B6, RDH16, DHRS9 and RDH5 expression in AS-BP, AS-CaP and CRPC. Androgen metabolism pathways 
for DHT synthesis (A). Diagram of 3α-oxidoreductase activity (B). COBALT 3α-oxidoreductase protein sequence alignment with the 
catalytic site highlighted (green box) (C). IHC of four endogenous 3α-oxidoreductases in AS-BP, AS-CaP and CRPC (D). Positive and 
negative control images were shown in Supplementary Figure 1. Scores showed that HSD17B6 and RDH16 were expressed at higher levels 
in CRPC than ASBP or AS-CaP tissue (E). Data were presented as the mean +/- SEM. Protein expression was modeled as a function of 
tissue type (AS-BP, AS-CaP or CRCP), compartment (cytosol or nuclear), their interaction, and a random rater effect using a linear mixed 
model (LMM). Mean expression was compared among tissue types and between compartments using Tukey-Kramer adjusted tests about 
the least square means. P-values were listed in Supplementary Table 4.
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with qRT-PCR data (Figure 2A) and previous reports 
[5] that LAPC-4 cells expressed endogenous RDH5 that 
metabolized DIOL to DHT. DHT levels were higher (p 
= 0.008) in SFM treated LAPC-4 cells that expressed 
RDH16 compared to SFM treated LAPC-4 cells with 
empty plasmid (Figure 3A [RDH16 vs. empty plasmid] 
and Supplementary Table 6), which suggested that RDH16 
enhanced DHT synthesis in LAPC-4 cells. 
Figure 2: 3α-oxidoreductases were expressed in CaP cell lines and xenografts. qRT-PCR results were shown for 
3α-oxidoreductase (A), SRD5A (B), and AR (C) mRNA levels for CaP cell lines and CWR22 and rCWR22 xenografts. Data were presented 
as mean +/- SEM. Gene expression was modeled as a function of cell line and a random replicate effect using a LMM. Mean expression 
was compared among cell lines using Tukey-Kramer adjusted tests about the least square means.
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LAPC-4 cells with empty plasmid treated with 
DIOL produced higher levels of DHT compared to 
SFM treated LAPC-4 cells with empty plasmid (Figure 
3B [note the change in Y axis between panels A and B]; 
Supplementary Table 6). DIOL treated LAPC-4 cells that 
expressed RDH16 produced higher (p = 0.022) levels of 
DHT than SFM treated LAPC-4 cells with empty plasmid 
(Figure 3A and Supplementary Table 6). DIOL treated 
LAPC-4 cells that expressed HSD17B6 produced lower 
DHT levels (p < 0.001) compared to LAPC-4 cells with 
empty plasmid, which suggested that LAPC-4 cells may 
possess inhibitory mechanisms that impaired HSD17B6 
activity.
DHT levels were higher (p = 0.024) when LAPC-4 
cells with empty plasmid were treated with T (Figure 3C 
and Supplementary Table 6) compared to SFM treated 
LAPC-4 cells with empty plasmid, which is consistent with 
T to DHT conversion by endogenous SRD5A [19]. DHT 
levels were not significantly different among T treated 
LAPC-4 cells that expressed 3α-oxidoreductases or LAPC-
4 cells with empty plasmid (Supplementary Table 6). 
5α-dione was produced when LAPC-4 cells 
with empty plasmid were treated with DIOL or AND 
(Figure 3B). The data were consistent with the levels of 
endogenous RDH5 mRNA found in LAPC-4 cells (Figure 
2A). DIOL treated LAPC-4 cells that transiently expressed 
HSD17B6, RDH16 or DHRS9 produced 5α-dione, 
but only LAPC-4 cells that expressed HSD17B6 (p = 
0.022) or RDH16 (p = 0.003) produced higher 5α-dione 
levels compared to LAPC-4 cells with empty plasmid 
(Figure 3B; Supplementary Table 6). The data suggested 
LAPC-4 cells endogenously converted DIOL to DHT 
and HSD17B6 or RDH16 converted AND to 5α-dione. 
AND treated LAPC-4 cells that transiently expressed 
Figure 3: DHT levels increased when RDH16 was expressed in LAPC-4 cells. Androgen levels were measured using LC-MS/
MS from media and cell pellets of LAPC-4 cells transfected with empty plasmid or expression plasmids encoded with HSD17B6, RDH16, 
DHRS9 or RDH5. Media and cell pellet androgen levels were combined. Cells were treated for 12 h in SFM alone (A) or SFM with 20 
nM DIOL (B) or 1 nM T (C) or 20 nM AND (D). Western blot analysis using DDK antibody was used to confirm enzyme expression (E). 
Western blot images were cropped to conserve presentation space. Data were presented as mean +/- SEM. Androgen levels were modeled 
as a function of treatment (SFM, DIOL, T or AND), enzyme (HSD17B6, RDH16, DHRS9 or RDH5), and their interaction using a general 
linear model (GLM). Mean androgen levels were compared among DIOL, T or AND treated LAPC-4 cells against SFM treated LAPC-4 
cells for each analyte. Comparisons were made among LAPC-4 cells that expressed each 3α-oxidoreductase and LAPC-4 cells with empty 
plasmid for each treatment using Dunnett adjusted post-hoc tests. P-values were reported in Supplementary Table 6. *p < 0.05.
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3α-oxidoreductases produced similar 5α-dione levels as 
AND treated LAPC-4 cells with empty plasmid (Figure 
3D). The data suggested that LAPC-4 cells may not be 
an appropriate CaP cell model to study the ability of 
3α-oxdioredcutases to convert AND to 5α-dione. 
Taken together, these data were consistent with 
reports that 3α-oxidoreductases metabolize DIOL to DHT 
or AND to 5α-dione [5, 10, 12, 13]. 
Catalytic amino acid substitution or deletion 
impaired 3α-oxidoreductase activity 
Previous reports showed that 3α-oxidoreductases 
contained a catalytic tyrosine (Y) and lysine (K) that lowered 
the binding energy requirements and promoted the metabolism 
of androgen precursors [12, 13, 34]. Site-directed mutagenesis 
of the 3α-oxidoreductase catalytic residues confirmed 
Y176/175 and K179/180 were essential for 3α-oxidoreductase 
activity for all four enzymes. The mutants included ∆cat 
(deletion of the catalytic residues) or double mutants, Y→F, 
K→R (Y176F for HSD17B6, RDH16, DHRS9 or Y175F for 
RDH5 and K180R for HSD17B6, RDH16 and DHRS9 or 
K179R for RDH5). Rationale for the Y→f mutation rested on 
their similarity in size but difference in an essential hydroxyl 
group. This mutation was not expected to alter protein folding 
but would affect enzyme activity. The K→R mutation was 
chosen because R would maintain a positive charge but was 
not expected to alter protein folding [34, 35]. 
qRT-PCR confirmed that CV-1 cells had low 
endogenous AR and 3α-oxidoreductase mRNA levels 
that suggested RDH5 converted AND to 5α-dione in 
control CV-1 cells (Figure 4A). 3α-oxidoreductase protein 
expression was not detected using western blotting (data 
not shown). Therefore, despite low expression of RDH5, 
CV-1 cells were used to express wild-type or mutant 
3α-oxidoreductases to evaluate the effect of the mutations 
on the activity of 3α-oxidoreductases. 
CV-1 cells treated with AND produced only a small 
amount of 5α-dione that was measurable only in the media 
(Figure 4B). T or DHT was not detected in the media or 
CV-1 cell pellets. Therefore, subsequent experiments 
measured only androgens in media. CV-1 cells that 
expressed wild-type HSD17B6, RDH16 or RDH5 and 
were treated with AND produced 5α-dione at levels higher 
than levels observed in media from CV-1 cells with empty 
plasmid (Supplementary Table 8). ∆cat or the Y→F,K→R 
mutations reduced 5α-dione levels to background. Wild-
type DHRS9 activity was impaired in CV-1 cells, which 
suggested CV-1 cells possessed inhibitory mechanisms 
that interfered with DHRS9 activity (Figure 4B). 
5α-dione levels were not increased in CV-1 cells that 
expressed Y→F,K→R or ∆cat 3α-oxidoreductase mutants. 
3α-oxidoreductase enzyme expression was verified using 
western blot (Figure 4C). The findings suggested that 
Y176 (Y175) and K180 (K179) were critical residues for 
enzyme activity for three of the four 3α-oxidoreductases. 
3α-oxidoreductase expression in AS-BP and CaP 
specimens from research subjects treated with 
finasteride
To address the clinical relevance of the 
3α-oxidoreductases, LC-MS/MS was applied to tissues 
obtained from a randomized, double-blind, placebo-
controlled clinical trial of selenium supplementation and 
finasteride treatment of research subjects with CaP for two 
to four weeks prior to radical prostatectomy (Selenium 
and Finasteride Pre-Treatment Trial, I104607). Research 
subjects who received finasteride alone or in combination 
with selenium were compared to research subjects who 
received selenium alone or placebo. Research subjects 
treated with finasteride had decreased CaP tissue levels 
of DHT in both benign and malignant macro-dissected 
samples, although DHT levels remained sufficient to 
activate AR (data not shown). TMAs generated from the 
clinical trial were sectioned and analyzed using IHC. 
HSD17B6, RDH16, DHRS9 and RDH5 were expressed in 
AS-BP and AS-CaP (Figure 5A–5B). HSD17B6, RDH16, 
DHRS9 and RDH5 expression levels and subcellular 
localization were similar to the 72 research subjects’ 
specimens analyzed previously (Figure 1D–1E). The 
data suggested that DHT synthesis persisted in spite of 
finasteride inhibition of SRD5A either from incomplete 
inhibition of SRD5A or from backdoor DHT synthesis. 
Combination dutasteride and 3α-oxidoreductase 
mutants decreased DHT greater than dutasteride 
alone
Primary backdoor DHT synthesis may facilitate 
CaP resistance to 5α-reductase inhibition. Therefore, 
simultaneous inhibition of the terminal steps of the 
frontdoor and primary backdoor pathways could lower 
DHT levels more effectively than targeting either terminal 
step alone. LAPC-4 cells exhibited SRD5A activity and 
dutasteride treatment decreased LAPC-4 DHT levels 
[19]. LAPC-4 cells also were capable of backdoor DHT 
synthesis using 3α-oxidoreductases to convert DIOL to 
DHT (Figure 3A). Therefore, LAPC-4 cells were used 
to test the effect of inhibition of the terminal steps of 
the frontdoor and primary backdoor androgen pathways. 
Dutasteride was used to inhibit SRD5A activity and block 
the frontdoor pathway. Activity impairing mutants were 
used to block enzymatic activity in the primary backdoor 
pathway, since no effective inhibitors are available for the 
four 3α-oxidoreductases. 
DHT levels were higher in LAPC-4 cell pellets that 
overexpressed RDH16 (p < 0.001) or DHRS9 (p < 0.001) 
compared to LAPC-4 cell pellets with empty plasmid 
(Figure 6A [SFM alone]; Supplementary Table 10); no 
androgens were measurable in media. DHT levels were 
lower in dutasteride treated LAPC-4 cells with empty 
plasmid compared to SFM treated LAPC-4 cells with empty 
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plasmid (Figure 6A; p = 0.041; Supplementary Table 10). 
No effect of dutasteride was observed in LAPC-4 cells that 
expressed wild-type RDH16 or DHRS9, which suggested 
that RDH16 or DHRS9 was sufficient for primary backdoor 
DHT synthesis. LAPC-4 cells that expressed ∆cat of RDH5 
or Y→F, K→R mutants of RDH16 or DHRS9 had lower 
DHT levels (RDH5, p = 0.046; RDH16, p = 0.006; DHRS9, 
p = 0.004) compared to LAPC-4 cells that expressed 
wild-type RDH16, DHRS9 or RDH5. DHT levels were 
lowered further by dutasteride treatment of LAPC-4 cells 
that expressed mutant RDH16 or DHRS9 compared to 
LAPC-4 cells treated with dutasteride alone. DHT levels 
were significantly lower in LAPC-4 cells that expressed 
RDH16-∆cat (p = 0.008), RDH16-Y176F,K180R (p = 
0.004), DHRS9-∆cat (p = 0.029) or DHRS9-Y176F,K180R 
(p = 0.004) after dutasteride treatment compared to 
LAPC-4 cells that overexpressed wild-type RDH16 or 
DHRS9 (Figure 6A; Supplementary Table 10). Subsequent 
experiments focused on RDH16 because [1] wild-type 
RDH16 expression rendered dutasteride ineffective 
in LAPC-4 cells; and [2] DHT levels were lowered 
significantly by expression of RDH16-Y176F,K180R and 
dutasteride treatment. 
Empty plasmid, or plasmids for over-expression 
of RDH16 wild-type or RDH16-Y176F, K180R were 
expressed into VCaP, LNCaP-C4-2 (C4-2) or CWR-R1 
cells and DHT levels were measured using LC-MS/
MS. DHT levels were similar in VCaP cells in SFM 
treated with or without dutasteride, which suggested that 
dutasteride treatment did not lower VCaP DHT levels 
(Figure 6B). The data were consistent with data reported 
previously [19]. Expression of wild-type RDH16 increased 
DHT levels (p = 0.031) that were affected minimally by 
dutasteride treatment. RDH16-Y176F,K180R expression 
resulted in DHT levels similar to VCaP cells that contained 
the empty plasmid. C4-2 cells produced measurable levels 
Figure 4: Mutation of conserved residues impaired 3α-oxidoreductase activity. CV-1 cells were analyzed for 3α-oxidoreductase 
gene expression (A). 5α-dione levels were measured in CV-1 cells that transiently expressed wild-type HSD17B6, RDH16, DHRS9 or 
RDH5 wild-type 3α-oxidoreductases catalytic site deletion mutant (∆cat) or double mutant (Y→F, K→R) (B). Transient 3α-oxidoreductase 
expression was confirmed using western blotting with DDK antibody (C). Western blot images were cropped to conserve presentation 
space. Data were presented as the mean +/- SEM. Mean media androgen levels were compared between AND or SFM treated CV-1 
cells using one-sided Tukey-Kramer adjusted Welch-Satterthwaite T-tests; corresponding P-values were listed in Supplementary Table 
6. Media androgen levels of AND treated CV-1 cells were modeled as a function of enzyme (HSD17B6, RDH16, DHRS9 or RDH5, or 
empty plasmid), plasmid type (wild-type, Y→F, K→R or ∆cat 3α-oxidoreductases) and their interaction using a GLM. Mean levels were 
compared among plasmid types for each 3α-oxidoreductase, and among 3-oxidoreductases and the empty plasmid for each plasmid type 
using Tukey-Kramer adjusted post-hoc tests. P-values were reported in Supplementary Table 8. *p < 0.05.
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of DHT that were reduced by dutasteride treatment (p = 
0.001; Figure 6C; Supplementary Table 10). Expression 
of wild-type RDH16 increased DHT levels (p = 0.001) 
that appeared to be reduced by dutasteride treatment. C4-2 
cells that expressed RDH16-Y176,K180R produced DHT 
levels similar to C4-2 cells with empty plasmid. RDH16 
did not appear to increase DHT levels in CWR-R1 cells 
and dutasteride did not lower DHT levels of CWR-R1 
cells that contained empty plasmid or expressed wild-type 
RDH16 (Figure 6D). DHT levels appeared lower when 
CWR-R1 cells that expressed RDH16-Y176F,K180R were 
treated with dutasteride. 
Figure 5: 3α-oxidoreductases were expressed in AS-BP and AS-CaP tissues from research subjects treated with 
finasteride. HSD17B6, RDH16 and RDH5 (A) were detected using IHC in androgen stimulated-benign prostate (AS-BP) and CaP (AS-
CaP) tissues. Visual scoring showed 3α-oxidoreductase expression levels did not change with or without finasteride treatment (B). Data 
were presented as mean +/- SEM. Protein expression levels were modeled as a function of treatment (finasteride and no finasteride), tissue 
type (AS-BP or AS-CaP), their interaction, and a random subject effect using a LMM. Mean levels were compared between treatments 
within each tissue type, and between tissue types for each treatment using Tukey-Kramer adjusted tests about the least-square means. 
P-values were reported in Supplementary Table 9. 
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Figure 6: The combination of dutasteride and 3α-oxidoreductase mutants decreased DHT levels greater than 
dutasteride alone. The effect of dutasteride on DHT levels was determined in LAPC-4 cells that transiently overexpressed wild-type, 
∆cat or Y→F, K→R enzymes. (A) DHT levels were measured in VCaP, C4-2 and CWR-R1 cells transfected with empty plasmid or 
over-expressing plasmids of wild-type RDH16 or RDH16 Y176F,K180R (B–D). Western blot analysis using DDK antibody confirmed 
transiently expressed enzymes in LAPC-4, VCaP, C4-2 and CWR-R1 (E–H). Western blot images were cropped to conserve presentation 
space. Data were presented as mean +/- SEM. DHT was modeled as a function of treatment (dutasteride or SFM), enzyme (HSD17B6, 
RDH16, DHRS9 or RDH5) or empty plasmid, and plasmid type (wild-type, ∆cat or Y→F, K→R) using a GLM. Mean DHT levels were 
compared between dutasteride and SFM treated LAPC-4 cells using one-sided Tukey-Kramer adjusted tests about the least-square means. 
Mean levels were compared among LAPC-4 cells that expressed HSD17B6, RDH16, DHRS9 or RDH5, or empty plasmid, for each 
3α-oxidoreductase-treatment combination using Tukey-Kramer adjusted tests about the least square means. P-values were reported in 
Supplementary Table 10. *p < 0.05.
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Western blot analysis demonstrated wild-type, ∆cat 
or Y→F,K→R mutant 3α-oxidoreductase expression in the 
four CaP cell lines (Figure 6E–6H). LC-MS/MS revealed 
that dutasteride appeared to lower T levels in all LAPC-4 
cells, except in LAPC-4 cells that expressed RDH5-∆cat 
(data available upon request). LNCaP cells did not have 
measurable DHT, and T was not detected after dutasteride 
treatment (data available upon request). 
DISCUSSION
The findings provide proof of principal that the 
catalytic site shared by HSD176, RDH16, DHRS9 and 
RDH5 plays a role in intracrine androgen metabolism. 
RDH16 or DHRS9 enhanced DHT synthesis in LAPC-
4 cells, which was consistent with previous reports from 
our group and others [5, 11–13, 34, 36, 37]. LAPC-4 
and CV-1 LC-MS/MS data suggested 3α-oxidoreductase 
activity may be cell line-specific because CV-1 cells could 
not use DHRS9 to convert AND to 5α-dione and LAPC-4 
cells could not use HSD17B6 to convert DIOL to DHT. 
However, HSD17B6 has been shown to convert DIOL 
to DHT in VCaP and LNCaP cell lines [38]. LC-MS/
MS revealed that all four 3α-oxidoreductases converted 
AND to 5α-dione. Mutation of the common catalytic 
amino acids diminished 3α-oxidoreductase activity, which 
impaired CaP cells’ DHT synthesis using the primary 
backdoor pathway. 
The current study is novel because the data showed 
that 3α-oxidoreductases are expressed in specimens of 
AS-BP, AS-CaP and CRPC, and AS-BP and AS-CaP after 
finasteride treatment. The primary backdoor pathway may 
facilitate DHT synthesis to overcome abiraterone treatment 
for CRPC and finasteride treatment for benign prostate 
enlargement or CaP chemoprevention. LC-MS/MS data 
provided evidence that all four 3α-oxidoreductases have 
similar enzymatic activity and that amino acid residues 
Y176/175 and K180/179 are essential for conversion of 
DIOL to DHT or AND to 5α-dione. The combination of 
dutasteride treatment and 3α-oxidoreductase mutation 
decreased DHT levels more effectively than dutasteride 
or 3α-oxidoreductase mutants alone. 
The studies demonstrated that 3α-oxidoreductase 
expression may provide AS-BP, AS-CaP and CRPC with 
a mechanism for resistance to SRD5A inhibitors that 
primarily block frontdoor DHT synthesis. 
A potential limitation of the study is that 
experiments could not be performed using endogenous 
3α-oxidoreductases because enzyme expression was 
so low in CaP cell lines. Therefore, 3α-oxidoreductases 
were expressed transiently in CaP and CV-1 cells. 
Expression variability in cell-to-cell expression 
was a potential complication in cells that expressed 
3α-oxidoreductases transiently. However, western blot 
analysis showed expression levels were consistent 
among wild-type enzymes. Western blots also showed 
3α-oxidoreductase mutant expression was lower than 
the expression of wild-type 3α-oxidoreductases, which 
suggested amino acid substitutions may impair post-
translational modification. However, sufficient enzyme 
was present based on the reproducibility of the replicates 
and differences in androgen metabolism observed among 
CaP cells transfected with control, wild-type or mutant 
3α-oxidoreductases.
LC-MS/MS analyses were consistent across nine 
analytical runs conducted over a twenty month period. 
Sample generation, LC-MS/MS sample preparation and 
analysis improved over twenty months, which led to 
reduced replicate variability observed in later experiments. 
Reduced replicate variability explains why DHT levels 
produced from SFM only treated LAPC-4 cells that 
expressed DHRS9 were significantly higher than LAPC-
4 cells with empty plasmid in Figure 6A, but not Figure 
3A.   Results were reliable over time and across replicates 
because the extracted calibration standards and plasma 
quality controls used to control and assess the quality of 
each LC-MS/MS analysis had an overall mean accuracy of 
100% and 97.9%, respectively, for the androgens analyzed 
in CaP cell pellets and media over nine independent sets 
of experiments. 
The LC-MS/MS method used for these studies was 
limited to six androgens and therefore, glucuronidated 
or sulfated androgens or androgen metabolites with 
activity in the glucocorticoid pathway were not measured. 
Cellular uptake and export of androgens and their 
metabolites were not considered [39]. The LC-MS/MS 
method could not measure DIOL because DIOL did not 
display a mass spectrum sufficiently different from other 
androgens. Therefore, AND conversion to 5α-dione 
was used to measure individual enzyme activity for the 
expression studies in CV-1 cells. The studies suggested 
that the conversion of AND to 5α-dione may provide an 
opportunity to use the secondary backdoor pathway to 
produce DHT [9]. 
The combination of dutasteride treatment and 
3α-oxidoreductase mutation showed DHT levels 
were suppressed for 12 h. Clinical effectiveness will 
require longer studies of any potential inhibitor of the 
four 3α-oxidoreductases alone or in combination with 
dutasteride. 
Taken together, the data [1] show that 
3α-oxidoreductases are expressed in AS-BP, AS-CaP and 
CRPC; [2] demonstrate the catalytic residues necessary 
for the terminal step of the primary backdoor pathway, 
DIOL to DHT, are essential to all four 3α-oxidoreductases; 
and [3] provide evidence that combined SRD5A and 
3α-oxidoreductase blockade lowered DHT levels more 
effectively than inhibition of either enzyme family alone. 
Inhibitors against the 3α-oxidoreductases are not yet 
available for clinical use and need to be identified. A new 
treatment strategy to block the key enzymatic steps of the 
frontdoor and primary and secondary backdoor pathways 
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may decrease DHT levels more effectively than ADT 
alone. Further reduction of tissue DHT by inhibiting the 
last step of intracrine DHT synthesis should improve the 
clinical response to ADT or induce re-remission of CRPC 
and improve survival of men with advanced CaP.
MATERIALS AND METHODS
Experimental models
Human male CaP lines LAPC-4 [40], LNCaP [41], 
PC-3 cells (ATCC, Manassas, VA) and LNCaP-C4-2 (C4-
2) cells [42, 43] were cultured in RPMI 1640 (Mediatech, 
Inc., Manassas, VA). CWR-R1 cells [44] were cultured 
using Richter’s Improved media (Corning, NY). CV-1 
monkey kidney cells, DU145 [45] and VCaP cells (ATCC) 
were cultured in DMEM (Corning). RPMI and DMEM 
media were supplemented with 10% fetal bovine serum 
(FBS, Corning) and 2 mM glutamine (Corning). CWR-R1 
cells were cultured in Richter’s Improved Media (Corning) 
supplemented with 1% epidermal growth factor (Thermo 
Fisher Scientific, Waltham, MA), 1% insulin-transferrin-
sodium selenite supplement (Roche, Indianapolis, IN), 1% 
nicotinamide (Calbiochem, Billerica, MA) and 2% FBS. 
Androgen-dependent CWR22 [46] and ADT-recurrent 
CWR22 (rCWR22) [47] human CaP xenografts were 
propagated in immunocompromised nude mice. 
All cell lines and xenografts were authenticated using 
genomic profiling in the RPCI Genomics Shared Resource. 
DNA profiles were acquired using 15 short tandem repeat 
(STR) loci and an amelogenin gender-specific marker. Test 
and control samples were amplified using the AmpFLSTR® 
Identifiler® Plus PCR Amplification Kit (Thermo Fisher 
Scientific, Waltham, MA) using the Verti 96-well Thermal 
Cycler (Applied Biosystems, Foster City, CA) in 9600 
Emulation Mode (initial denature: 95°C 11 min, 28 cycles 
of denature: 94°C 20 sec and anneal/extend: 59°C 3 min, 
final extension: 60°C 10 min and hold: 12°C). PCR products 
were evaluated using the 3130xl Genetic Analyzer (Applied 
Biosystems) and analyzed using GeneMapper v4.0 (Applied 
Biosystems). Eight of the 15 STRs and amelogenin from 
the DNA profile for the cell lines were compared to the 
ATCC STR database and the DSMZ combined Online STR 
Matching Analysis databases. All matches above 80% were 
considered the same lineage. 
Method details
COBALT 
The COBALT protein sequence alignment 
tool [48] was accessed using the National Center for 
Biotechnology (NCBI) website (http://www.ncbi.nlm.
nih.gov/tools/cobalt/cobalt.cgi). Accession numbers for 
the 3α-oxidoreductases, HSD17B6, RDH16, DHRS9 and 
RDH5, were acquired using the NCBI protein database 
(http://www.ncbi.nlm.nih.gov/protein) and UniProtKB 
(http://www.uniprot.org/). Amino acid sequences of the 
four 3α-oxidoreductases were analyzed using COBALT 
and compared to other 3α-oxidoreductases and the SRD5A 
and CYP17 families to determine whether the catalytic 
site was conserved and specific to HSD17B6, RDH16, 
DHRS9 and RDH5.
Site-directed mutagenesis
Site-directed mutagenesis was performed using the 
QuikChange® Lightning Site-Directed Mutagenesis Kit 
(Strategene, Foster City, CA) and Strategene’s protocol. 
pCMV6-entry expression plasmids with C-terminal MYC-
DDK tag encoded with HSD17B6, RDH16, DHRS9 or RDH5 
were purchased from Origene (Origene, Rockville, MD). 
3α-oxidoreductase primers (Integrated DNA Technologies, 
Coralville, IA) were used to generate ∆cat or Y→F, K→R 
3α-oxidoreductase mutants (Supplementary Table 1). Plasmids 
were purified using PureYield Plasmid Miniprep System 
(Promega, Madison, WI) and sequenced at the Genomics 
Shared Resource. PCR for plasmid sequencing was performed 
using plasmid templates and Big Dye Terminator v3.1 Master 
Mix Kit (Life Technologies, Carlsbad, CA). PCR products 
were purified using Sephadex-G50 (Sigma-Aldrich, St. Louis, 
MO) into multiscreen HV plates (Thermo Fisher Scientific). 
Eluted samples were analyzed using 3130xl ABI Prism Genetic 
Analyzer. Sequence data were analyzed using Sequencing 
Analysis 5.2 software (Life Technologies). 
qRT-PCR
RNA extraction was performed using the RNeasy Plus 
Mini Kit (Qiagen, Valencia, CA). Samples generated from 
9 cell lines were plated at 1 x 106 cells/T25 cell culture flask 
(Corning). Cells were harvested using 0.05% trypsin and 
washed 3 times using Dulbecco’s phosphate buffered saline 
(PBS). PBS was removed and RLT lysis buffer was added to 
lyse the cell pellets. Frozen tissues from 2 xenografts (CWR22 
and rCWR22) were Dounce homogenized in RLT lysis buffer. 
Lysates were passed through QIAshredder columns and RNA 
was extracted using RNeasy spin columns. Genomic DNA 
contamination was assessed using PCR and intron spanning 
GAPDH primers. Genomic DNA contamination was removed 
using a DNA-free DNA Removal Kit (Life Technologies). 
RNA was analyzed using PCR after DNase treatment to 
confirm genomic DNA was removed. 
First strand complementary DNA (cDNA) was 
generated using 2 µg RNA and the High-Capacity cDNA 
Reverse Transcription Kit (10X RT Buffer, 10X Random 
Primers, 25X 100 mM deoxyNTP mix and 50 U/µL 
MultiScribe-Reverse Transcriptase; Applied Biosystems) 
and RNAse inhibitor in 10 µL reactions. The Primer Quest 
Primer Design Tool was used to design qRT-PCR primers 
(Integrated DNA Technologies) (Supplementary Table 1). 
qRT-PCR reactions included 12.5 µL of SYBR 
Green PCR Master Mix (Applied Biosystems), 0.1 µL 
of 10 mM forward and reverse primers, 2.5 µL of 100 
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ng/µL cDNA (250 ng final concentration) and 9.8 µL 
distilled deionized (dd-H2O) for a final reaction volume 
25 µL. Reactions were performed in 96-well plates. 
Gene expression was analyzed using 7300 Real Time 
System (Applied Biosystems). The qRT-PCR reaction 
parameters were 95°C for 30 sec, 60°C for 30 sec repeated 
39 times, 95°C for 5 sec and melt curve 65°C-95°C. All 
procedures were performed with 3 technical replicates and 
3 biological replicates. Cycle threshold (Ct) values were 
normalized against β2 microglobulin (B2M) that was 
selected based on unchanged B2M expression in SFM 
(data not shown). Ct values for negative RT controls and 
no template controls were reported as undefined. Relative 
gene abundance was calculated using 2^-(normalized Ct).
Cell lysate and media preparation for LC-MS/
MS analysis
LAPC-4, LNCaP, C4-2 or CWR-R1 cells were plated 
at 1.2 × 105/well, VCaP cells at 2.5 × 105 and CV-1 cells at 
1 × 104/well in 6-well tissue culture plates (Corning). Media 
and cell pellets from two 6-well plates were combined to 
generate 1 media and 1 cell pellet sample for LC-MS/MS 
analysis. LAPC-4, LNCaP, C4-2 or CWR-R1 cells were 
transfected using the Effectene Transfection Kit (Invitrogen, 
Grand Island, NY). Forty-eight h after transfection, growth 
media was removed and LAPC-4 cells were washed once 
with PBS (Corning). LAPC-4 cells were treated with serum-
free complete media (SFM, Corning) alone or with 1 nM 
T, 20 nM DIOL 20 nM AND (Steraloids, Newport, RI) or 
1 µM dutasteride (Selleckchem, Houston, TX) for 12 h. 
VCaP or CV-1 cells were transfected using X-tremeGene 
HP transfection reagent (Roche Diagnostics Corporation, 
Indianapolis, IN). After 48 h, growth media were aspirated, 
CV-1 cells were washed once with PBS and incubated in 
SFM alone or with 20 nM AND (Steraloids) for 12 h. 
After 12 h treatment, media (total 24 mL) were collected 
in 50 mL conical tubes (Corning). Cells were released using 
trypsin and collected in 15 mL conical tubes (Corning). The 
cells were washed 3 times using PBS, re-suspended in 1 mL 
PBS and 5% of the cell suspension was removed for protein 
concentration measurement and western blot analysis. The 
remaining 95% of the cell suspension was centrifuged and 
the supernatant was removed and discarded. Cell pellets were 
stored at -80ºC until analyzed using LC-MS/MS. 
LC-MS/MS
Cell pellet and media samples were analyzed over 
9 runs for 5 androgens T, DHT, DHEA, ASD and AND 
using a validated LC-MS/MS method (Supplementary 
Methods and [49]). 5α-dione also was measured using 
this assay and data were included although results did 
not pass the strict validation acceptance criteria used for 
other androgens. Study samples were quantitated using 
aqueous-based spiked calibration standards and pre-spiked 
quality control samples prepared in 2X charcoal-stripped 
human postmenopausal female plasma (Bioreclamation, 
LLC, Westbury, NY). Performance data for calibrators, 
quality controls and calibration ranges were listed in 
Supplementary Table 2. 
Androgen concentrations (pmoles/mg protein) in 
cell lysates measured using LC-MS/MS (ng/mL) were 
multiplied by the total volume of the lysate (1 mL), 
normalized by the total amount of protein of the cell pellet 
(mg), divided by the molecular weight of the androgen 
(ng/nmole), and converted to pmoles. Media androgen 
concentrations (ng/mL) were multiplied by the total 
volume of media (24 mL), normalized against total protein 
of the cell culture (mg), divided by the molecular weight 
of the androgen (ng/nmole) and converted to pmoles. Cell 
pellet and media androgen concentrations were reported 
combined in Results. Data from cell pellets or media and 
their statistical analysis provided upon similar results and 
are available on request. Experiments were performed in 
triplicate (n = 3). 
Western blotting
Cells removed from -80°C storage were resuspended 
in ubiquitin extraction lysis buffer (150 mM NaCl, 50 
mM Tris-HCl, pH 7.4, 5 mM EDTA, 1% NP40, 0.5% 
sodium deoxycholate [all from Fisher, Pittsburg, PA]) 
and 0.1% SDS (Quality Biological, Gathersburg, MD). 
Halt Protease Inhibitor Cocktail (Sigma) was added to 
the ubiquitin lysis buffer just before cells were lysed. 
Cells were freeze-thawed three times and centrifuged 
at 14,000 x g for 15 min. Supernatants were transferred 
to clean microfuge tubes. Protein was quantified using 
the Protein Determination Kit (BioRad) and analyzed 
in flat bottom 96-well plates using an EL800 University 
Microplate Reader (BioTek Instruments) and KC Junior 
software (BioTek Instruments). SDS-polyacrylamide 
gel electrophoresis (PAGE) was performed using 4-15% 
Mini Trans-Blot cell (BioRad). Protein was transferred to 
Immuno-Blot PVDF membranes for Protein Blot (BioRad) 
and blocked in 5% milk in Tris-buffered saline with Tween 
20 (TBST, Amersham Bioscience, GE Healthcare Bio-
Sciences, Pittsburg, PA) for 30 min.
Membranes were incubated with DDK targeted 
antibody (Origene) 1:1000 overnight at room temperature. 
After incubation, blots were washed three times with 
TBST (Amersham Bioscience) for 10 min each. Washed 
blots were incubated with goat anti-mouse secondary 
antibody (Jackson ImmunoResearch Laboratories, West 
Grove, PA) 1:1000 for 1 h at room temperature. Blots were 
washed with TBST three times for 10 min each and protein 
expression was measured using the Pierce ECL Western 
Blotting Substrate (Life Technologies). Immunoblots were 
washed with TBST, blocked in 5% milk in TBST, reprobed 
for tubulin (1:1000 for 1 h at room temperature; Abcam, 
Cambridge, MA) and incubated with goat anti-rabbit 
Oncotarget11239www.impactjournals.com/oncotarget
secondary antibody (1:1000 for 1 h at room temperature; 
Jackson ImmunoResearch Laboratories). 
Tissue microarray (TMA) construction
Matched AS-BP and AS-CaP tissue specimens 
were collected from 36 patients who underwent radical 
prostatectomy. CRPC specimens were collected from 
36 patients who underwent transurethral resection of 
the prostate for urinary retention from CaP that recurred 
during ADT. Specimens were collected between 1991 and 
2011 at the Roswell Park Cancer Institute or the University 
of North Carolina at Chapel Hill, NC. TMAs were 
constructed (0.6 millimeter tissue cores) from formalin-
fixed, paraffin-embedded donor blocks from each patient, 
which was guided by genitourinary pathologists. TMAs 
contained control tissue from lung, tonsil, liver, kidney, 
colon, spleen, cervix, thyroid, ovary, testis, myometrium 
and brain.
TMAs were constructed using the same process 
on tissues collected from a randomized, double-
blind, placebo-controlled clinical trial of selenium 
supplementation and finasteride treatment of patients 
with CaP prior to robotic prostatectomy (Selenium and 
Finasteride Pre-Treatment Trial ID:NCT00736645). Forty-
seven patients scheduled for radical prostatectomy were 
randomized into one of four treatment groups: placebo, 
finasteride, selenium or combination finasteride and 
selenium. 
IHC
TMA sections were de-paraffinized, rehydrated 
under an alcohol gradient and antigen retrieved using 
Reveal Decloaker (Biocare Medical, Concord, CA) 
for 30 min at 110°C and 5.5–6.0 psi. Sections were 
immunostained for the four 3α-oxidoreductases and 
AR as described (Supplementary Table 3). Enzymatic 
activity was assayed using 3,3’-Diaminobenzidine 
(Sigma-Aldrich) and sections were counterstained with 
hematoxylin (Vector Laboratories, Burlingame, CA). 
Sections were dehydrated and mounted using permanent 
mounting medium. Section images were collected using 
a Leica DFC0425C camera mounted on a Leica DMRA2 
microscope (Leica Microsystems Inc., Buffalo Grove, IL). 
Protein expression was determined by three scorers who 
assessed the immunostain intensity and assigned values 
between 0 (no immunostain) and 3 (dark immunostain) 
for 100 cells per core that generated an average final score 
between 0 and 300 [50–52].
Quantification and statistical analysis
IHC and qRT-PCR expression data were 
summarized graphically using mean and standard error. 
IHC experiments produced average scores between 0 and 
300 for each tissue specimen from each patient in each 
TMA; qRT-PCR experiments had a sample size of n = 9 
(three biological replicates analyzed using three technical 
replicates) per treatment group. Specific treatment groups 
details or changes in sample size for each experiment were 
listed in the figure legends.
IHC and qRT-PCR expression data, and androgen 
concentrations, were modeled as a function of tissue type 
(AS-BP, AS-CaP or CRPC), cell-line (VCaP, LNCaP, 
LAPC-4, C4-2, PC-3, DU145, CWR-R1, CWR22 or 
rCWR22), enzyme (HSD17B6, RDH16, DHRS9 or 
RDH5) or empty plasmid, treatment (SFM, T, DIOL, AND 
or dutasteride), expressed 3α-oxidoreductase (wild-type, 
Δcat or Y→F, K→R mutant enzymes), interaction terms 
and random replicate effects using general linear models 
(GLMs) or linear mixed models (LMMs). Factors, factor 
levels, interaction terms and random effects were included 
in each model depended on the specific experiment and 
research question that was addressed. Mean differences of 
interest were evaluated using Dunnett or Tukey-Kramer 
adjusted tests about the appropriate least square means. All 
tests were two-sided, unless stated otherwise. All model 
assumptions were verified graphically using quantile-
quantile and residual plots, with Box-Cox transformations 
applied as appropriate. Additional details for experiment 
specific analyses were provided in the appropriate figure 
legends.
All analyses were conducted in SAS v9.4 (Cary, 
NC) at a nominal significance level of 0.05; therefore 
a P-value less than 0.05 denoted a statistical significant 
result. No randomization techniques were utilized and no 
observations were excluded from analysis.
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